Company profile
SEC EDGAR ↗- Industry
- Pharmaceutical Preparations
- Listed
- NYSE: NVS
- Incorporated
- Switzerland
- Headquarters
- Basel, V8
- Fiscal year end
- Dec 31
The analyses
The Adjacency Expansion · Growth & Portfolio
Novartis Sold Off Its Adjacencies One by One — The Only Bet That Paid Was a Molecule
The story is that Novartis grew into adjacencies. The truth runs the other way: vaccines sold to GSK in 2015, the consumer JV cashed out for $13 billion in 2018, Alcon spun off in 2019, Sandoz in 2023. The only adjacency that paid was a molecule.
7 min
The Adjacency Expansion · Growth & Portfolio
Novartis Paid $8.7 Billion to Cure a Disease Once. The Hard Part Is Doing It Twice.
Novartis bought the world's best-selling gene therapy for $8.7 billion. Then it discovered the trap: cure a one-shot disease and you exhaust your own market. Zolgensma peaked at $1.35 B in 2021 and has fallen ever since. The real test is whether the platform has a second act.
8 min
The Cannibalization Choice · Decision Forks
Novartis Spent a Decade Selling Off Its Own Insurance Policy. The Bet Is Now Naked.
Over ten years Novartis shed Alcon, vaccines, consumer health, and finally Sandoz - trading revenue diversity for a pure-play bet. In 2024 it paid off: $50.3 billion in revenue, 12% growth. But the buffer is gone.
8 min
The Price Tag · Business Model
Novartis Priced Zolgensma at $2.125M With a Watchdog's Blessing — Then Sat on Manipulated Data
Zolgensma's $2.125M price triggered outrage as 'the world's most expensive drug.' But the math was defensible — and an independent watchdog endorsed it. The real story is the manipulated data Novartis sat on, and the zero-penalty ending.
8 min